RESOLVENCT07908381
A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High Risk for Severe Disease
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Time to complete resolution of all 13 RSV symptoms as assessed by the Respiratory Infection Intensity and Impact Questionnaire (RiiQ) symptom scale
Timeframe: Day 1 through Day 21
Secondary (19)
Number of participants with hospitalization due to RSV
Number of participants with hospitalization or death due to any cause
Number of participants who died
Number of participants with non-protocol defined medical visits for any cause
Time to complete resolution of RSV LRTD symptoms by RiiQ
Show 14 moreShow less
Time to complete resolution of all 29 RSV parameters as assessed by RiiQ symptom scale score
Time to alleviation of LRTD symptoms by RiiQ
Time to alleviation of all 13 RSV symptoms as assessed by RiiQ
Time to alleviation of all 29 RSV parameters as assessed by RiiQ
Time to complete resolution of RSV infection symptoms as assessed by PGI-S scale
Time to resolution to pre-existing symptoms
Number of participants requiring mechanical ventilation
Number of participants requiring supplemental oxygen in hospital
Number of participants requiring ICU admission
Change from baseline in RSV viral load
Percentage of participants with RSV RNA viral load TND
Time to RSV RNA viral load TND
Safety as measured by frequency of adverse events (AEs)
Plasma Concentrations of zelicapavir
Arms and interventions
zelicapavirExperimental
Zelicapavir 800 mg, orally
PlaceboPlacebo comparator
Matching placebo, orally
Drugs: zelicapavir, Placebo
Sites
4 sites in 1 country